Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

NeuBase Therapeutics Inc (NBSE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow NeuBase Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.420 0.000    0.00%
01/01 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.404 - 0.420
Type:  Equity
Market:  United States
NeuBase Therapeutics 0.420 0.000 0.00%

NASDAQ:NBSE Financials

 
This summary provides an overview of the most significant critical numbers from each of the OHR financial reports, including theNeuBase Therapeutics Inc income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the NASDAQ:NBSE financials over time via breakdowns of their annual reports.

NeuBase Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 1.82 million compared to USD 7.63 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 4.73 a year ago. Diluted loss per share from continuing operations was USD 0.66 compared to USD 4.73 a year ago.For the nine months, net loss was USD 9.36 million compared to USD 26.05 million a year ago. Basic loss per share from continuing operations was USD 4.57 compared to USD 16.08 a year ago. Diluted loss per share from continuing operations was USD 4.57 compared to USD 16.08 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

NBSE Income Statement & Profits

Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM 0%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue
Gross Profit
Operating Income -1.59 -3.69 -3.92 -3.95
Net Income -1.82 -3.45 -3.77 -4.37

NBSE Balance Sheet

Quick Ratio MRQ 0
Current Ratio MRQ -
LT Debt to Equity MRQ 0%
Total Debt to Equity MRQ 0%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 18.62 22.33 21.46 25.58
Total Liabilities 9.48 11.09 7.01 7.36
Total Equity 9.14 11.25 14.45 18.22

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM 0
Revenue/Share TTM -
Operating Cash Flow  -43.01%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -2 -3.55 -3.55 -5.69
Cash From Investing Activities 0 -0.002 -0.002 -0.05
Cash From Financing Activities -0.174 2.23 2.23 -0.029
Net Change in Cash -2.18 -1.32 -1.32 -5.77
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NBSE Price Commentary

Write your thoughts about NeuBase Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email